2024.09.19
On August 30, 2024, Jacobio Pharma (1167.HK) announced that it had granted m88 bonus China rights (including mainland China, Hong Kong, Macau and Taiwan) of m88 bonus KRAS G12C inhibitor Glecirasib and SHP2 inhibitor JAB-3312 to Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH).
According to m88 bonus terms of m88 bonus agreement, Jacobio shall receive around RMB 200 million, which includes an upfront payment of RMB 150 million, and compensation of around RMB 50 million for R&D and delivery expenses. Jacobio will receive potential development and sales milestone payments of up to RMB 700 million and double-digit royalty payments on net sales from Allist.
m88 bonus was engaged by Jacobio Pharma to review, modify and negotiate the agreement for the project. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, m88 bonus’s team was trusted and recognized by the client.
Partnerm88 sport bettingled the m88 bonus team.
